Smiley said: “One of the main reasons that global companies are so engaged in China right now is the fact that you can find an early clinical programme for less total value exchange than in the US or Europe.As 2026 approaches, Josh Smiley, president and COO of US-China biopharma Zai Labs, predicts that dealmaking between China and the West will continue to grow, with deal volume rising in tandem.In the last five years, there has been a sizable increase in high-value deals between the West and China, with 20 ...

Company Overview - BeOne Medicines Ltd. - Sponsored ADR (ONC) shares increased by 4% to $290.35 in the last trading session, with a notable trading volume that exceeded the average [1] - The stock has experienced a 10.4% gain over the past four weeks, indicating positive momentum [1] Sales Growth Potential - The recent stock price rally is driven by investor optimism regarding the sales growth potential of the company's oncology products, including Brukinsa (zanubrutinib) and Tevimbra (tislelizumab) [2] - BeOne Medicines is also developing several other pipeline candidates aimed at treating various cancer indications [2] Earnings and Revenue Expectations - The company is projected to report quarterly earnings of $0.19 per share, reflecting a year-over-year increase of 116.5% [3] - Expected revenues for the upcoming quarter are $1.23 billion, which represents a 32.7% increase compared to the same quarter last year [3] Earnings Estimate Revisions - The consensus EPS estimate for BeOne Medicines has been revised down by 60.7% over the last 30 days [4] - A negative trend in earnings estimate revisions typically does not lead to price appreciation, suggesting caution for future stock performance [4] Industry Context - BeOne Medicines is part of the Zacks Medical - Drugs industry, which includes other companies like Metagenomi (MGX) [5] - Metagenomi's stock closed 1.4% higher at $2.13, with a notable return of 41.9% over the past month [5] - Metagenomi's consensus EPS estimate has remained unchanged at -$0.68, representing a year-over-year change of -134.5% [6]